Results 131 to 140 of about 281,370 (287)
Triple‐negative breast cancer has a poor prognosis. Xanthatin directly targets and degrades CISD1, triggering ferroptosis through iron dysregulation. The concurrently activated mitophagy synergistically amplifies ferroptotic cell death. Xanthatin also demonstrates potent in vivo anti‐tumor efficacy with minimal toxicity, highlighting its therapeutic ...
Qinwen Liu +9 more
wiley +1 more source
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick
Dillon PM, Brenin CM, Slingluff CL Jr
doaj
The study identifies a NIPAL1‐driven metabolic‐epigenetic circuit in esophageal squamous cell carcinoma that promotes glycolysis, lactate accumulation, and H3K18 histone lactylation, forming a self‐sustaining loop that suppresses CD8+ T cell immunity.
Ri‐Xin Chen +15 more
wiley +1 more source
Coacervate‐Mediated Lysosome‐Targeting Antibody Delivery for Protein Degradation
Targeting coacervates to the lysosome in the cytoplasm is a challenge. Here, we convert a tetrapeptide into lysosome‐targeting, membrane‐translocating coacervates. The lysosome‐sorting peptide coacervates facilitate coacervate‐mediated delivery of antibody antigen complexes and a PROTAC compound to the lysosome for the targeted degradation of cancer ...
Dingdong Yuan +7 more
wiley +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Integrating Spatial Proteogenomics in Cancer Research
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang +13 more
wiley +1 more source
SpatialESD: Spatial Ensemble Domain Detection in Spatial Transcriptomics
ABSTRACT Spatial transcriptomics (ST) measures gene expression while preserving spatial context within tissues. One of the key tasks in ST analysis is spatial domain detection, which remains challenging due to the complex structure of ST data and the varying performance of individual clustering methods. To address this, we propose SpatialESD, a Spatial
Hongyan Cao +11 more
wiley +1 more source
BiSCALE: A pathology‐driven deep learning framework for multi‐scale gene expression prediction from whole‐slide images. It accurately infers bulk and near‐cellular spot‐level expression, links predictions to clinical phenotypes, identifies disease‐associated niches, and enables applications in risk stratification and cell‐identity annotation, providing
Hailong Zheng +8 more
wiley +1 more source
Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu +6 more
wiley +1 more source

